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Introduction {#jah31527-sec-0004}
============

Although systemic thrombolysis remains the most effective medical treatment for acute ischemic stroke,[1](#jah31527-bib-0001){ref-type="ref"} many postthrombolytic patients develop intracranial hemorrhage (ICH), a dreaded complication that frequently leads to early deterioration, and have unfavorable long‐term outcomes.[2](#jah31527-bib-0002){ref-type="ref"}, [3](#jah31527-bib-0003){ref-type="ref"}, [4](#jah31527-bib-0004){ref-type="ref"} Numerous efforts have been made by researchers to identify factors that could cause alterations in the efficacy and safety of systemic thrombolysis,[5](#jah31527-bib-0005){ref-type="ref"} among which prestroke medications have always been a major area of interest.[6](#jah31527-bib-0006){ref-type="ref"} However, it is thus far a disturbing fact---given the large proportion of stroke patients who receive long‐term antiplatelet therapy---that no consensus has been reached on the exact risk‐benefit profile of intravenous thrombolysis in patients taking antiplatelet medications before the onset of stroke. Aside from the European guideline that merely referred to prior antiplatelet therapy as a "warning sign" of low safety,[7](#jah31527-bib-0007){ref-type="ref"} the latest guidelines have yet to provide a clear message as to how those patients would react differently to thrombolytic therapy and how their diseases might progress afterward.[7](#jah31527-bib-0007){ref-type="ref"}, [8](#jah31527-bib-0008){ref-type="ref"}

Previous studies that sought to examine the correlations between prestroke antiplatelet therapy and postthrombolytic outcomes were mostly small, and their findings were largely inconsistent.[9](#jah31527-bib-0009){ref-type="ref"}, [10](#jah31527-bib-0010){ref-type="ref"}, [11](#jah31527-bib-0011){ref-type="ref"}, [12](#jah31527-bib-0012){ref-type="ref"}, [13](#jah31527-bib-0013){ref-type="ref"}, [14](#jah31527-bib-0014){ref-type="ref"}, [15](#jah31527-bib-0015){ref-type="ref"}, [16](#jah31527-bib-0016){ref-type="ref"}, [17](#jah31527-bib-0017){ref-type="ref"}, [18](#jah31527-bib-0018){ref-type="ref"}, [19](#jah31527-bib-0019){ref-type="ref"}, [20](#jah31527-bib-0020){ref-type="ref"}, [21](#jah31527-bib-0021){ref-type="ref"}, [22](#jah31527-bib-0022){ref-type="ref"}, [23](#jah31527-bib-0023){ref-type="ref"}, [24](#jah31527-bib-0024){ref-type="ref"}, [25](#jah31527-bib-0025){ref-type="ref"}, [26](#jah31527-bib-0026){ref-type="ref"}, [27](#jah31527-bib-0027){ref-type="ref"}, [28](#jah31527-bib-0028){ref-type="ref"} Meta‐analyses based on only a limited number of those studies were therefore subject to inaccuracies and biases, because they did not allow us to synthesize adjusted results or to perform comprehensive subgroup analyses.[5](#jah31527-bib-0005){ref-type="ref"}, [6](#jah31527-bib-0006){ref-type="ref"} Now with data from some of the largest registries having surfaced, our attention is once again brought to the subject of intravenous thrombolysis in patients receiving antiplatelet medications.[25](#jah31527-bib-0025){ref-type="ref"}, [26](#jah31527-bib-0026){ref-type="ref"}, [29](#jah31527-bib-0029){ref-type="ref"} Xian et al concluded recently that those patients had better functional outcomes despite higher risks for symptomatic intracranial hemorrhage (sICH),[29](#jah31527-bib-0029){ref-type="ref"} yet it needs to be pointed out that they adopted certain study designs and outcome definitions that were not completely compatible with those of many previous studies. The extent to which the newer study findings could be generalized and how they compared with prior data warrant further analysis.

We thereby conducted this meta‐analysis to determine whether preexisting antiplatelet therapy was associated with altered short‐ and long‐term outcomes in patients with acute ischemic stroke who underwent thrombolysis and attempted to identify patient and study characteristics that might have contributed to the inconsistencies of previous findings through subgroup analysis.

Methods {#jah31527-sec-0005}
=======

The study is presented in accordance with the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses.[30](#jah31527-bib-0030){ref-type="ref"}

Data Sources and Search Strategy {#jah31527-sec-0006}
--------------------------------

A review protocol was established and was scrutinized and approved by the Institutional Review Board of the First Affiliated Hospital of Sun Yat‐sen University before initiation of this study. Two reviewers independently searched PubMed and EMBASE in November 2015 for the Medical Subject Headings (MeSH) term "brain infarction," along with the following terms and their derivatives: "ischemic stroke" AND "plasminogen activator" or "alteplase" or "thrombolysis" AND "antiplatelets" or "aspirin" or "acetylsalicylate" or "dipyridamole" or "clopidogrel" or "ticlopidine" or "prasugrel" or "ticagrelor" or "cilostazol" or "GP IIb/IIIa inhibitors" or "abciximab" or "eptifibatide" or "tirofiban." All titles and abstracts from this search were reviewed for relevance based on the inclusion/exclusion criteria described later. Full texts of appropriate abstracts were then reviewed and the final list of articles for inclusion was determined by consensus of all authors. Our selection of studies was not limited to date or language. We also searched the references of included studies to identify potentially relevant citations.

Eligibility Criteria {#jah31527-sec-0007}
--------------------

Studies were considered eligible if they met the following criteria: (1) studies performed on patients with acute ischemic stroke aged ≥18 years, (2) included patients who were treated with tissue plasminogen activator (tPA), (3) compared patients taking prestroke antiplatelet medications with those who were not, and (4) reported ≥1 of the outcomes defined next.

Outcomes {#jah31527-sec-0008}
--------

Major outcomes for patients with postthrombolytic acute ischemic stroke in this study include (1) sICH, (2) modified Rankin Scale score (mRS), and (3) death from all causes. Although variations in how outcomes were defined existed across studies, we considered any reported sICH within 7 days and any mRS score or mortality within 90 days from stroke onset as eligible outcomes.

Data Extraction {#jah31527-sec-0009}
---------------

Two investigators individually collected data on patient demographic characteristics such as age, sex, serum glucose levels, National Institutes of Health Stroke Scale scores, thrombolysis time from onset, and specific types of prestroke antiplatelet medications by using standardized data collection forms. Study characteristics such as original study type, definitions of sICH, and time from stroke onset to outcome follow‐up were also abstracted. Both raw and adjusted outcomes and their adjusting variables were recorded. Any disagreement was resolved by consensus among all authors.

Quality of Data Assessment {#jah31527-sec-0010}
--------------------------

The methodological quality of included studies was evaluated by using the Newcastle--Ottawa Scale (NOS) system for cohort studies,[31](#jah31527-bib-0031){ref-type="ref"} in which studies were judged on 3 broad perspectives: the selection of the study groups (0--4 points), the comparability of the groups (0--2 points), and the ascertainment of the outcome of interest (0--3 points). The quality scores were not used as weights in the analysis, as recommended by the Meta‐analysis of Observational Studies in Epidemiology (MOOSE) study group,[32](#jah31527-bib-0032){ref-type="ref"} but rather as differentiators in subgroup analyses (score ≤7 versus \>7).

Statistical Analysis {#jah31527-sec-0011}
--------------------

We assumed the effects being estimated in the included studies to be heterogeneous and used the random‐effects models instead of the fixed‐effects models to estimate pooled odds ratios (ORs) and 95% CIs so as to be more conservative. When multiple sets of data regarding different outcome definitions were reported within a single study, those based on definitions most frequently adopted in other included studies were used in the main analysis, and each set of these estimates were subsequently included in subgroup analyses that evaluated the influence of outcome definitions on the pooled results. For a study that reported separate adjusted ORs for patients taking single‐ and dual‐antiplatelet agents,[16](#jah31527-bib-0016){ref-type="ref"} combined ORs of the 2 groups were calculated by using the fixed‐effects model to provide overall estimates for the study in the main analysis. ORs and both the lower and upper limits of corresponding 95% CIs from each study were logarithmically transformed to normalize distribution before they were combined. Heterogeneity was assessed by using the χ^2^ test and quantified by using the *I* ^2^ statistic, which represents the percentage of total variation across studies that is attributable to heterogeneity rather than chance.[33](#jah31527-bib-0033){ref-type="ref"} Subgroup analyses were carried out based on outcome definitions, onset‐to‐treatment time, specific antiplatelet agents, and the NOS scores of included studies. Funnel plot analysis and the Egger test were performed to assess publication bias if \>10 studies were included in a single analysis. In case of significant funnel plot asymmetry, the trim‐and‐fill method was used to test the reliability of study results.[34](#jah31527-bib-0034){ref-type="ref"} All statistical analyses were conducted by using Stata 12.0 (StataCorp).

Results {#jah31527-sec-0012}
=======

Search Results {#jah31527-sec-0013}
--------------

The primary search strategy produced 2243 studies for review, of which 21 satisfied all inclusion criteria. For the 2 pairs of studies that analyzed overlapped data from the same registries, we included the latest and those with the largest samples for meta‐analysis.[14](#jah31527-bib-0014){ref-type="ref"}, [18](#jah31527-bib-0018){ref-type="ref"}, [22](#jah31527-bib-0022){ref-type="ref"}, [26](#jah31527-bib-0026){ref-type="ref"} The detailed selection process is summarized in Figure [1](#jah31527-fig-0001){ref-type="fig"}. Additional searches of references did not provide additional studies.

![Selection process of studies included in the meta‐analysis. AF indicates atrial fibrillation; IV, intravenous; IA, intra‐arterial; tPA, tissue plasminogen activator.](JAH3-5-e003242-g001){#jah31527-fig-0001}

Study Characteristics and Baseline Demographics {#jah31527-sec-0014}
-----------------------------------------------

The final 19 studies involved a total of 108 588 patients, of whom 46 478 were receiving antiplatelet therapy before stroke onset. The characteristics of those studies are presented in Table [1](#jah31527-tbl-0001){ref-type="table-wrap"} and the raw outcomes are shown in Table [2](#jah31527-tbl-0002){ref-type="table-wrap"}. Seven studies provided ≥1 adjusted odds estimates for the main outcomes. The characteristics of those studies are recorded in Table [3](#jah31527-tbl-0003){ref-type="table-wrap"}.

###### 

Characteristics of Studies Included for Meta‐Analysis

  First Author (Year)                                             Prior AP Therapy   No. of Patients, N   Median Age, y   Female, %   Mean Serum Glucose, mg/dL   Mean NIHSS   Onset to Treatment Time, min   AP Agents     sICH Definition                                     Outcome Follow‐up Time, d
  --------------------------------------------------------------- ------------------ -------------------- --------------- ----------- --------------------------- ------------ ------------------------------ ------------- --------------------------------------------------- ---------------------------
  Xian[29](#jah31527-bib-0029){ref-type="ref"} (2016)             Yes                38 844               73.7            49.7        138.6                       11.5         138                            A/C/AC/AD/O   NA[a](#jah31527-note-0002){ref-type="fn"} 0--36 h   At discharge
  No                                                              46 228             67.2                 51.4            135.6       11.2                        138                                                                                                           
  Meseguer[27](#jah31527-bib-0027){ref-type="ref"} (2015)         Yes                191                  74.5            43.4        124                         12           160                            NA            E 0--24 h                                           90
  No                                                              375                65.8                 46.1            119         11                          160                                                                                                           
  Watson‐Fargie[28](#jah31527-bib-0028){ref-type="ref"} (2015)    Yes                132                  NA              NA          NA                          NA           NA                             NA            E/N 0--24 h                                         NA
  No                                                              216                                                                                                                                                                                                           
  Lindley[26](#jah31527-bib-0026){ref-type="ref"} (2015)          Yes                775                  NA              NA          NA                          NA           NA                             A/C/D/O       NA 0--7 d                                           7
  No                                                              740                                                                                                                                                                                                           
  Pan[25](#jah31527-bib-0025){ref-type="ref"} (2015)              Yes                157                  66.0            40.8        140.7                       12           168                            A/C/AC/O      E/N/S24--36 h                                       90
  No                                                              951                62.7                 38.3            138.9       11                          168                                                                                                           
  Frank[23](#jah31527-bib-0023){ref-type="ref"} (2013)            Yes                727                  NA              NA          NA                          NA           NA                             SI/DU         E 0--4 d                                            NA
  No                                                              1826                                                                                                                                                                                                          
  Meurer[24](#jah31527-bib-0024){ref-type="ref"} (2013)           Yes                388                  74              47.7        137                         13           148                            NA            N 0--10 d                                           NA
  No                                                              442                65                   46.2            126         12                          151                                                                                                           
  Šaňák[21](#jah31527-bib-0021){ref-type="ref"} (2012)            Yes                56                   69.8            50.0        NA                          16           154.7                          A/C/AD        S 0--24                                             NA
  No                                                              90                 65.8                 43.3            15          157.6                                                                                                                                     
  Ibrahim[20](#jah31527-bib-0020){ref-type="ref"} (2010)          Yes                95                   71.5            51.3        NA                          16.8         NA                             A/C/AC/AD     S 0--72 h                                           90
  No                                                              180                68.3                 33.8            15.8                                                                                                                                                  
  Dorado[19](#jah31527-bib-0019){ref-type="ref"} (2010)           Yes                72                   70.5            NA          NA                          NA           NA                             A/C/AC/O      E 0--36 h                                           90
  No                                                              163                66.9                                                                                                                                                                                       
  Diedler[18](#jah31527-bib-0018){ref-type="ref"} (2010)          Yes                3782                 71              41.2        118                         12           140                            A/C/AC/AD/O   E/N/S 0--7 d                                        90
  No                                                              7954               66                   35.1            116         12                          140                                                                                                           
  Hermann[17](#jah31527-bib-0017){ref-type="ref"} (2009)          Yes                36                   71              NA          NA                          NA           NA                             A/C/AC/AD     S 12--36 h                                          NA
  No                                                              27                 67                                                                                                                                                                                         
  Cucchiara[16](#jah31527-bib-0016){ref-type="ref"} (2009)        Yes                337                  NA              NA          NA                          NA           NA                             SI/AC/AD/O    NA 0--36 h                                          NA
  No                                                              628                                                                                                                                                                                                           
  Bluhmki[15](#jah31527-bib-0015){ref-type="ref"} (2009)          Yes                130                  NA              NA          NA                          NA           NA                             NA            N 22--36 h                                          90
  No                                                              288                                                                                                                                                                                                           
  Uyttenboogaart[13](#jah31527-bib-0013){ref-type="ref"} (2008)   Yes                89                   73              48.4        115                         12           165                            A/C/D/AD      S 0--36 h                                           90
  No                                                              212                66                   47.2            115         13                          175                                                                                                           
  Bravo[12](#jah31527-bib-0012){ref-type="ref"} (2008)            Yes                137                  72.2            35          137                         14           148.5                          A/C/D/O       E 24--36 h                                          NA
  No                                                              468                66.6                 43.8            134         15                          151.1                                                                                                         
  Martí‐Fàbregas[11](#jah31527-bib-0011){ref-type="ref"} (2007)   Yes                49                   NA              NA          NA                          NA           NA                             NA            NA 24--36 h                                         NA
  No                                                              298                                                                                                                                                                                                           
  Schmülling[10](#jah31527-bib-0010){ref-type="ref"} (2003)       Yes                95                   66              NA          NA                          13           NA                             A/O           N 36--48 h                                          90
  No                                                              202                62                   10                                                                                                                                                                    
  Tanne[9](#jah31527-bib-0009){ref-type="ref"} (2002)             Yes                386                  NA              NA          NA                          NA           NA                             A/O           N 0--36 h                                           NA
  No                                                              813                                                                                                                                                                                                           

AP indicates antiplatelet; NIHSS, National Institutes of Health Stroke Scale; sICH, symptomatic intracranial hemorrhage; A, aspirin; C, clopidogrel; AC, aspirin--clopidogrel; AD, aspirin--dipyridamole; O, other antiplatelet medications; NA, not available; E, ECASS II, Second European‐Australasian Acute Stroke Study[3](#jah31527-bib-0003){ref-type="ref"}; N, NINDS, National Institute of Neurological Disorders and Stroke rt‐PA Stroke Study Group[2](#jah31527-bib-0002){ref-type="ref"}; D, dipyridamole; S, SITS‐MOST, Safe Implementation of Thrombolysis in Stroke‐Monitoring Study[4](#jah31527-bib-0004){ref-type="ref"}; SI, single; DU, dual.

sICH definition was recorded as NA if it did not accord with any of the 3 definitions: ECASS II, SITS‐MOST, and NINDS.

###### 

Raw Outcomes

  First Author (Year)                                             Prior AP Therapy   No. of Patients, N   No. of Patients with sICH, N (%)   No. of Patients Followed for Outcome, N   No. of Patients With Good Outcomes, N (%)   No. of Patients Followed for Mortality, N   No. of Deaths, N, (%)
  --------------------------------------------------------------- ------------------ -------------------- ---------------------------------- ----------------------------------------- ------------------------------------------- ------------------------------------------- -----------------------
  Xian[29](#jah31527-bib-0029){ref-type="ref"} (2016)             Yes                38 844               1927 (5.0)                         15 475                                    5081 (32.8)                                 38 844                                      3115 (8.0)
  No                                                              46 228             1720 (3.7)           17 613                             6548 (37.2)                               46 228                                      3061 (6.6)                                  
  Meseguer[27](#jah31527-bib-0027){ref-type="ref"} (2015)         Yes                191                  14 (7.3)                           191                                       113 (59.2)                                  191                                         24 (12.6)
  No                                                              375                18 (4.8)             375                                241 (64.2)                                375                                         43 (11.5)                                   
  Watson‐Fargie[28](#jah31527-bib-0028){ref-type="ref"} (2015)    Yes                132                  14 (10.6)                          NA                                        NA                                          NA                                          NA
  No                                                              216                4 (1.9)                                                                                                                                                                                   
  Lindley[26](#jah31527-bib-0026){ref-type="ref"} (2015)          Yes                775                  70 (9.0)                           NA                                        NA                                          775                                         107 (13.8)
  No                                                              740                34 (4.6)             740                                56 (7.5)                                                                                                                          
  Pan[25](#jah31527-bib-0025){ref-type="ref"} (2015)              Yes                157                  10 (6.3)                           153                                       87 (56.9)                                   154                                         22 (14.3)
  No                                                              951                32 (3.4)             933                                545 (58.4)                                933                                         91 (9.8)                                    
  Frank[23](#jah31527-bib-0023){ref-type="ref"} (2013)            Yes                727                  47 (6.5)                           NA                                        NA                                          NA                                          NA
  No                                                              1826               66 (3.6)                                                                                                                                                                                  
  Meurer[24](#jah31527-bib-0024){ref-type="ref"} (2013)           Yes                388                  35 (9.0)                           NA                                        NA                                          NA                                          NA
  No                                                              442                27 (6.1)                                                                                                                                                                                  
  Šaňák[21](#jah31527-bib-0021){ref-type="ref"} (2012)            Yes                56                   3 (5.4)                            NA                                        NA                                          NA                                          NA
  No                                                              90                 2 (2.2)                                                                                                                                                                                   
  Ibrahim[20](#jah31527-bib-0020){ref-type="ref"} (2010)          Yes                95                   9 (9.5)                            84                                        33 (39.3)                                   NA                                          NA
  No                                                              180                9 (5.0)              160                                85 (53.1)                                                                                                                         
  Dorado[19](#jah31527-bib-0019){ref-type="ref"} (2010)           Yes                72                   8 (11.1)                           72                                        34 (47.2)                                   NA                                          NA
  No                                                              163                8 (5.0)              163                                94 (57.7)                                                                                                                         
  Diedler[18](#jah31527-bib-0018){ref-type="ref"} (2010)          Yes                3782                 325 (8.6)                          3782                                      1783 (47.1)                                 3782                                        515 (13.6)
  No                                                              7954               507 (6.4)            7954                               3922 (49.3)                               7954                                        727 (9.1)                                   
  Hermann[17](#jah31527-bib-0017){ref-type="ref"} (2009)          Yes                36                   3 (8.3)                            NA                                        NA                                          NA                                          NA
  No                                                              27                 0 (0)                                                                                                                                                                                     
  Cucchiara[16](#jah31527-bib-0016){ref-type="ref"} (2009)        Yes                337                  31 (9.2)                           NA                                        NA                                          NA                                          NA
  No                                                              628                23 (3.7)                                                                                                                                                                                  
  Bluhmki[15](#jah31527-bib-0015){ref-type="ref"} (2009)          Yes                130                  11 (8.5)                           130                                       68 (52.3)                                   130                                         11 (8.5)
  No                                                              288                22 (7.6)             288                                151 (52.4)                                288                                         21 (7.3)                                    
  Uyttenboogaart[13](#jah31527-bib-0013){ref-type="ref"} (2008)   Yes                89                   12 (13.5)                          89                                        45 (50.6)                                   NA                                          NA
  No                                                              212                6 (2.8)              212                                95 (44.8)                                                                                                                         
  Bravo[12](#jah31527-bib-0012){ref-type="ref"} (2008)            Yes                137                  9 (6.6)                            NA                                        NA                                          NA                                          NA
  No                                                              468                17 (3.6)                                                                                                                                                                                  
  Martí‐Fàbregas[11](#jah31527-bib-0011){ref-type="ref"} (2007)   Yes                49                   2 (4.1)                            NA                                        NA                                          NA                                          NA
  No                                                              298                6 (2.0)                                                                                                                                                                                   
  Schmülling[10](#jah31527-bib-0010){ref-type="ref"} (2003)       Yes                95                   6 (6.3)                            95                                        46 (48.4)                                   95                                          17 (17.9)
  No                                                              202                5 (2.5)              202                                107 (53.0)                                202                                         19 (9.4)                                    
  Tanne[9](#jah31527-bib-0009){ref-type="ref"} (2002)             Yes                386                  33 (8.5)                           NA                                        NA                                          NA                                          NA
  No                                                              813                37 (4.6)                                                                                                                                                                                  

When multiple definitions of symptomatic intracranial hemorrhage[2](#jah31527-bib-0002){ref-type="ref"} (sICH) were used within 1 study, the numbers of sICH patients were recorded based on the National Institute of Neurological Disorders and Stroke rt‐PA Stroke Study Group definition. When multiple definitions of favorable functional outcome were adopted within 1 study, those with modified Rankin Scale scores of 0 to 2 were considered to be patients with a good outcome. When mortality rates were recorded at multiple time points within 1 study, mortality on day 90 from stroke onset was recorded. NA indicates not available.

###### 

Characteristics of Studies that Presented Adjusted Odds Estimates

  First Author (Year)                                             No. of Patients taking AP medications, N   No. of Controls, N   Adjusted Estimates                         Stratification by OTT   Stratification by AP Agents   Stratification by Outcome Definitions           Adjusting Variables
  --------------------------------------------------------------- ------------------------------------------ -------------------- ------------------------------------------ ----------------------- ----------------------------- ----------------------------------------------- --------------------------------------
  Xian[29](#jah31527-bib-0029){ref-type="ref"} (2016)             22 813                                     20 221               sICH, good functional outcome, mortality   0--3 h                  A, C, AC, AD                  mRS 0--1, mRS 0--2                              G, X, OTT, APM, HC, HS
  Pan[25](#jah31527-bib-0025){ref-type="ref"} (2015)              157                                        951                  sICH, mortality                            NA                      A, AC                         NINDS, ECASS II, SITS‐MOST                      NA
  Meurer[24](#jah31527-bib-0024){ref-type="ref"} (2013)           388                                        442                  sICH                                       NA                      NA                            NA                                              G, S, N, OTT
  Dorado[19](#jah31527-bib-0019){ref-type="ref"} (2010)           72                                         163                  sICH                                       NA                      NA                            NA                                              X, E, HC, PVD, R
  Diedler[18](#jah31527-bib-0018){ref-type="ref"} (2010)          3782                                       7954                 sICH, good functional outcome, mortality   NA                      A, C, AC, AD                  NINDS, ECASS II, SITS‐MOST/mRS 0--1, mRS 0--2   NA
  Cucchiara[16](#jah31527-bib-0016){ref-type="ref"} (2009)        337                                        628                  sICH, good functional outcome,             NA                      Single, double                NA                                              G, N, SBP, DBP, HTN, SG, HC, HS, ASP
  Uyttenboogaart[13](#jah31527-bib-0013){ref-type="ref"} (2008)   89                                         212                  sICH, good functional outcome              0--3 h                  NA                            NA                                              G, N, SG, R, SBP, HTN

AP indicates antiplatelet; OTT, onset‐to‐treatment time; sICH, symptomatic intracranial hemorrhage; A, aspirin; C, clopidogrel, AC, aspirin‐clopidogrel; AD, aspirin‐dipyridamole; mRS, modified Rankin Scale; G, age; X, sex; APM, type of antiplatelet medication; HC, history of coronary heart disease; HS, history of stroke/ transient ischemic attack; NA, not available; NINDS, National Institute of Neurological Disorders and Stroke rt‐PA Stroke Study Group[2](#jah31527-bib-0002){ref-type="ref"}; ECASS II, Second European‐ Australasian Acute Stroke Study[3](#jah31527-bib-0003){ref-type="ref"}; SITS‐MOST, Safe Implementation of Thrombolysis in Stroke‐Monitoring Study[4](#jah31527-bib-0004){ref-type="ref"}; S, tobacco smoking; N, National Institute of Health Stroke Scale; E, history of ethanol abuse; PVD, history of peripheral vascular disease; R, prehospital radiology results; SBP, systolic blood pressure; DBP, diastolic blood pressure; HTN, history of hypertension; SG, serum glucose; ASP, the Alberta Stroke Program Early CT Score (ASPECTS).

All of the studies were retrospective analyses conducted with prospectively collected data. Patients taking long‐term antiplatelet medications were significantly older and had more comorbidities than did those who were not, in most studies, which suggested that both unadjusted and adjusted estimates needed to be taken into consideration when our results were interpreted. Baseline serum glucose levels and National Institutes of Health Stroke Scale scores did not differ significantly either at the study level or between groups in each study. However, certain study‐level variations existed in terms of onset‐to‐treatment time and outcome definitions, which indicated heterogeneous study designs and patient populations, and therefore the need for subgroup analysis. Among the 19 studies, only 10 defined prestroke antiplatelet therapy, most of which considered documentation of antiplatelet medications within 7 days before stroke onset as evidence of long‐term antiplatelet therapy. Only 1 study mentioned aspirin dosage as part of its inclusion criteria.[10](#jah31527-bib-0010){ref-type="ref"}

Quality Assessment Outcomes {#jah31527-sec-0015}
---------------------------

The outcomes of study quality assessment are as follows: 8 studies scored 9 (Xian et al,[29](#jah31527-bib-0029){ref-type="ref"} Pan et al,[25](#jah31527-bib-0025){ref-type="ref"} Meurer et al,[24](#jah31527-bib-0024){ref-type="ref"} Ibrahim et al,[20](#jah31527-bib-0020){ref-type="ref"} Dorado et al,[19](#jah31527-bib-0019){ref-type="ref"} Diedler et al,[18](#jah31527-bib-0018){ref-type="ref"} Cucchiara et al,[16](#jah31527-bib-0016){ref-type="ref"} and Uyttenboogaart et al[13](#jah31527-bib-0013){ref-type="ref"}), 3 studies scored 8 (Bluhmki et al,[15](#jah31527-bib-0015){ref-type="ref"} Bravo et al,[12](#jah31527-bib-0012){ref-type="ref"} and Tanne et al[9](#jah31527-bib-0009){ref-type="ref"}), and 7 studies scored 7 (Meseguer et al,[27](#jah31527-bib-0027){ref-type="ref"} Watson‐Fargie et al,[28](#jah31527-bib-0028){ref-type="ref"} Lindley et al,[26](#jah31527-bib-0026){ref-type="ref"} Martí‐Fàbregas et al,[11](#jah31527-bib-0011){ref-type="ref"} Schmülling et al,[10](#jah31527-bib-0010){ref-type="ref"} Šaňák et al,[21](#jah31527-bib-0021){ref-type="ref"} and Hermann et al[17](#jah31527-bib-0017){ref-type="ref"}). Those scores served as differentiators in a subgroup analysis that divided studies into 2 groups (NOS \>7 and NOS ≤7).

Outcomes of Meta‐Analysis {#jah31527-sec-0016}
-------------------------

### Symptomatic intracranial hemorrhage {#jah31527-sec-0017}

Of the 19 studies, 7 defined sICH per National Institute of Neurological Disorders and Stroke rt‐PA Stroke Study Group (NINDS)[2](#jah31527-bib-0002){ref-type="ref"} criteria, 7 reported sICH based on the Second European‐Australasian Acute Stroke Study (ECASS II)[3](#jah31527-bib-0003){ref-type="ref"} definition, 5 used the Safe Implementation of Thrombolysis in Stroke‐Monitoring Study (SITS‐MOST) definition,[4](#jah31527-bib-0004){ref-type="ref"} and 5 studies did not define sICH according to any of these prespecified criteria. Given the number of included sICH cases diagnosed per NINDS criteria was the largest, for the 3 studies that reported multiple sets of data regarding different sICH definitions,[18](#jah31527-bib-0018){ref-type="ref"}, [25](#jah31527-bib-0025){ref-type="ref"}, [28](#jah31527-bib-0028){ref-type="ref"} those based on the NINDS criteria were included for the main analysis. According to the pooled unadjusted OR, preexisting antiplatelet therapy was significantly associated with postthrombolytic sICH (OR 1.70, 95% CI 1.47--1.97) (Figure [2](#jah31527-fig-0002){ref-type="fig"}A). Although the pooled adjusted OR was not as great, it also reached statistical significance (OR 1.21, 95% CI 1.02--1.44) (Figure [3](#jah31527-fig-0003){ref-type="fig"}A). Higher heterogeneity was observed in the adjusted estimates (adjusted *I* ^2^=65.3%, *P*=0.008 versus unadjusted *I* ^2^=40.6%, *P*=0.034), yet the sources of heterogeneity were able to be identified when studies were stratified by sICH definition and antiplatelet agents. Though also suggesting higher postthrombolytic sICH tendency in patients on long‐term antiplatelet therapy, certain subgroup analyses did not yield results of statistical significance likely because of insufficient sample sizes (Table [4](#jah31527-tbl-0004){ref-type="table-wrap"}). When stratified by antiplatelet agents, our analysis revealed that odds of postthrombolytic sICH were lower in patients receiving prestroke clopidogrel (adjusted OR 0.81, 95% CI 0.64--1.02) than in those who were receiving prior aspirin--clopidogrel dual therapy (adjusted OR 1.88, 95% CI 1.18--3.00). All subgroup analysis results are shown in Table [4](#jah31527-tbl-0004){ref-type="table-wrap"}.

![Forest plots showing crude outcomes in patients who underwent thrombolysis with or without prestroke antiplatelet therapy. A, Symptomatic intracranial haemorrhage. B, Favorable functional outcome (defined by modified Rankin Scale score ≤2). C, Mortality. AP indicates antiplatelet. Horizontal axes are placed on log scale.](JAH3-5-e003242-g002){#jah31527-fig-0002}

![Forest plots showing adjusted outcomes in patients who underwent thrombolysis with or without prestroke antiplatelet therapy. A, Symptomatic intracranial haemorrhage. B, Favorable functional outcome (defined by modified Rankin Scale score ≤2). C, Mortality. AP indicates antiplatelet. Horizontal axes are placed on log scale.](JAH3-5-e003242-g003){#jah31527-fig-0003}

###### 

Subgroup Analyses

  Outcomes                              Factor              Crude OR (95% CI)   Studies, n    *I* ^2^, % (*P* Value)   Adjusted OR (95% CI)   Studies, n
  ------------------------------------- ------------------- ------------------- ------------- ------------------------ ---------------------- -------------
  Symptomatic intracranial hemorrhage   sICH definition                                                                                       
  NINDS                                 1.59 (1.26--1.99)   7                   28.1 (0.21)   1.05 (0.97--1.15)        3                      0.0 (0.78)
  ECASS II                              1.75 (1.42--2.16)   7                   16.8 (0.30)   1.10 (0.99--1.21)        3                      0.0 (0.55)
  SITS‐MOST                             2.47 (1.92--3.17)   5                   0.0 (0.82)    2.27 (0.86--5.97)        3                      75.6 (0.02)
  Onset‐to‐treatment time                                                                                                                     
  0--3 h                                1.59 (1.34--1.88)   10                  44.8 (0.06)   3.18 (0.38--26.35)       2                      87.5 (0.01)
  \>3 h                                 1.26 (1.08--1.46)   3                   0.0 (0.54)                                                    
  Antiplatelet agents                                                                                                                         
  Aspirin                               1.53 (1.30--1.82)   8                   41.0 (0.11)   1.02 (0.75--1.38)        3                      68.1 (0.04)
  Clopidogrel                           1.25 (0.82--1.91)   5                   39.9 (0.16)   0.81 (0.64--1.02)        2                      0.0 (0.46)
  Aspirin--clopidogrel                  3.32 (1.75--6.31)   5                   76.9 (0.02)   1.88 (1.18--3.00)        3                      56.0 (0.10)
  Aspirin--dipyridamole                 1.02 (0.60--1.73)   5                   20.7 (0.29)   0.99 (0.65--1.50)        2                      67.4 (0.08)
  NOS score                                                                                                                                   
  \>7                                   1.59 (1.37--1.84)   12                  43.1 (0.06)                                                   
  Favorable outcome                     Follow‐up time                                                                                        
  3 month                               0.91 (0.85--0.97)   8                   0.0 (0.46)    1.07 (0.83--1.37)        3                      46.5 (0.15)
  Good outcome definition                                                                                                                     
  mRS scores 0--2                       0.86 (0.79--0.93)   8                   36.0 (0.14)   1.09 (0.96--1.23)        4                      76.2 (0.01)
  mRS scores 0--1                       0.85 (0.81--0.90)   4                   13.4 (0.33)   1.06 (0.92. 1.22)        2                      90.4 (0.00)
  Onset‐to‐treatment time                                                                                                                     
  0--3 h                                0.84 (0.67--1.06)   3                   34.4 (0.22)   1.02 (0.97--1.07)        2                      0.0 (0.63)
  Antiplatelet agents (mRS 0--2)                                                                                                              
  Aspirin                               0.85 (0.68--1.05)   4                   41.5 (0.16)   1.11 (1.00--1.24)        2                      51.3 (0.15)
  Clopidogrel                           0.72 (0.56--0.92)   2                   0.0 (0.38)    1.09 (0.95--1.25)        2                      0.0 (0.58)
  Aspirin--clopidogrel                  0.81 (0.58--1.11)   2                   36.4 (0.21)   1.04 (0.79--1.36)        2                      54.5 (0.14)
  Aspirin--dipyridamole                                                                       0.98 (0.56--1.39)        2                      62.2 (0.10)
  Antiplatelet agents (mRS 0--1)                                                                                                              
  Aspirin                                                                                     1.14 (1.06--1.23)        2                      0.0 (0.41)
  Clopidogrel                                                                                 1.12 (0.97--1.29)        2                      0.0 (0.57)
  Aspirin--clopidogrel                                                                        1.04 (0.90--1.20)        2                      0.0 (0.37)
  Aspirin--dipyridamole                                                                       0.71 (0.51--1.00)        2                      48.8 (0.16)
  NOS score                                                                                                                                   
  \>7                                   0.87 (0.79--0.96)   7                   47.5 (0.08)                                                   
  Mortality                             Follow‐up time                                                                                        
  90 day                                1.54 (1.38--1.73)   5                   0.0 (0.60)    1.06 (0.99--1.15)        2                      0.0 (0.71)
  Antiplatelet agents                                                                                                                         
  Aspirin                               1.52 (1.34--1.73)   3                   0.0 (0.46)    0.97 (0.89--1.06)        3                      0.0 (0.98)
  Clopidogrel                                                                                 1.00 (0.83--1.23)        2                      0.0 (0.62)
  Aspirin--clopidogrel                  2.67 (1.82--3.90)   2                   0.0 (0.57)    1.14 (0.82--1.59)        3                      41.1 (0.18)
  Aspirin--dipyridamole                                                                       0.93 (0.63--1.38)        2                      25.1 (2.48)
  NOS score                                                                                                                                   
  \>7                                   1.38 (1.14--1.68)   4                   78.2 (0.00)                                                   

OR indicates odds ratio; sICH, symptomatic intracranial hemorrhage; sICH, symptomatic intracranial hemorrhage; ECASS II, Second European‐Australasian Acute Stroke Study[3](#jah31527-bib-0003){ref-type="ref"}; NINDS, National Institute of Neurological Disorders and Stroke rt‐PA Stroke Study Group[2](#jah31527-bib-0002){ref-type="ref"}; SITS‐MOST, Safe Implementation of Thrombolysis in Stroke‐Monitoring Study[4](#jah31527-bib-0004){ref-type="ref"}; NOS, Newcastle‐Ottawa Scale; mRS, modified Rankin Scale.

### Favorable outcome {#jah31527-sec-0018}

All studies with follow‐up patients for functional outcomes defined favorable outcome as mRS scores of either 0 to 2 or 0 to 1 on poststroke day 90, except for 1 study that recorded patient functional outcomes at hospital discharge.[29](#jah31527-bib-0029){ref-type="ref"} Our pooled analysis of crude ORs showed that patients taking prior antiplatelet medications tended to have lower odds of reaching favorable functional outcomes (OR 0.86, 95% CI 0.80--0.93) (Figure [2](#jah31527-fig-0002){ref-type="fig"}B). However, when adjusted for confounders, the independent association between pre‐existing antiplatelet therapy and unfavorable outcomes became insignificant (adjusted OR 1.09, 95% CI 0.96--1.24). Although a high level of heterogeneity was observed in the adjusted estimates (*I* ^2^=76.2%, *P*=0.006), we were able to locate the major sources of heterogeneity through subgroup analysis (Table [4](#jah31527-tbl-0004){ref-type="table-wrap"}), which included the 1 study that provided only data on outcome at hospital discharge.[29](#jah31527-bib-0029){ref-type="ref"} The pooled adjusted estimates remained similar after the exclusion of this study (OR 1.07, 95% CI 0.83--1.37). Of note, when stratifying for antiplatelet agents and outcome definitions, we found a positive association between prestroke aspirin and favorable functional outcomes defined by mRS 0 to 1 (adjusted OR 1.14, 95% CI 1.06--1.23) and mRS 0 to 2 (adjusted OR 1.11, 95% CI 1.00--1.24), whereas the combination of aspirin--dipyridamole was not positively associated with mRS scores of 0 to 1 (adjusted OR 0.71, 95% CI 0.51--1.00). Other subgroup analysis results are recorded in Table [4](#jah31527-tbl-0004){ref-type="table-wrap"}.

### Mortality {#jah31527-sec-0019}

Of the 7 studies that provided information on mortality, one assessed in‐hospital mortality,[29](#jah31527-bib-0029){ref-type="ref"} one reported both 7‐ and 90‐day data,[26](#jah31527-bib-0026){ref-type="ref"} and the others reported mortality on poststroke day 90. Although pooled unadjusted results indicated increased odds of all‐cause mortality among patients receiving prestroke antiplatelet medications (OR 1.46, 95% CI 1.22--1.75) (Figure [2](#jah31527-fig-0002){ref-type="fig"}C), pooled adjusted ORs did not reveal any significant correlations (OR 1.02, 95% CI 0.98--1.07) (Figure [3](#jah31527-fig-0003){ref-type="fig"}C). The robustness of such findings were proven via subgroup analyses, of which the results are shown in Table [4](#jah31527-tbl-0004){ref-type="table-wrap"}.

Publication Bias {#jah31527-sec-0020}
----------------

The funnel plot of pooled unadjusted estimates for sICH was significantly asymmetric (Figure [4](#jah31527-fig-0004){ref-type="fig"}) (Egger test *P*\<0.001), suggesting possible publication bias. To assess the impact of publication bias on our results, the trim‐and‐fill method was applied. After 9 studies were trimmed and 18 were filled, the OR of sICH was not significantly altered (OR 1.46, 95% CI 1.25--1.71). The results of the trim‐and‐fill analysis are shown in Figure [4](#jah31527-fig-0004){ref-type="fig"}.

![Filled funnel plots of crude estimates for symptomatic intracranial hemorrhage. Squared dots represent studies added in the trim‐and‐fill analysis.](JAH3-5-e003242-g004){#jah31527-fig-0004}

Discussion {#jah31527-sec-0021}
==========

The present meta‐analysis provides evidence that patients with acute ischemic stroke receiving long‐term antiplatelet medications were associated with greater risks of developing sICH after systemic thrombolysis, despite a relatively small overall excess. Although those patients were frequently observed to also have higher odds of death or developing unfavorable functional outcomes as suggested by our combined crude estimates, the independent association between prestroke antiplatelet therapy and worsened long‐term outcomes proved insignificant after adjustment for confounders. Therefore, a history of antiplatelet therapy should not be considered as contraindication for systemic thrombolysis in those patients.

Because sICH is the most serious complication of thrombolytic therapy in patients with acute ischemic stroke, it remains a topic of great clinical significance whether patients taking prestroke antiplatelet medications have a substantially elevated risk of sICH. Considering both the unadjusted and adjusted outcome estimates of the present study and the findings from a previous clinical trial that demonstrated higher sICH risk in patients receiving aspirin concomitant with tPA,[35](#jah31527-bib-0035){ref-type="ref"} an independent and causal relationship between platelet inhibition and postthrombolytic sICH seems plausible. However, it might be difficult to fully elucidate this phenomenon at the mechanistic level, given the complexity of the development of sICH and the lack of evidence from translational research and animal experiments. It has been suggested in a previous study that recanalization was necessary for the development of sICH at the injured vasculature beyond sites of occlusions.[36](#jah31527-bib-0036){ref-type="ref"} Thus, one possible explanation is that it was reperfusion by tPA itself, having been facilitated by platelet inactivation, that contributed to the increased incidence of sICH.[37](#jah31527-bib-0037){ref-type="ref"} Given that timely recanalization is strongly associated with favorable functional outcomes,[38](#jah31527-bib-0038){ref-type="ref"} if these assumptions were true, the excess risk for sICH attributed to prestroke platelet inhibition might not translate into worse functional outcomes, which is indeed supported by the pooled adjusted estimates of the present study. Moreover, the existence of prior antiplatelet therapy might in some cases even improve the outcomes of postthrombolytic patients, which is again consistent with some of our subgroup analysis results, as will be discussed later.

Although it was observed in many of the included studies that patients receiving prestroke antiplatelet therapy were prone to developing unfavorable outcomes such as disability and death, the demographic contexts need to be taken into consideration. The fact that those patients were taking antiplatelet therapy already implied that they did not represent the same population as other stroke patients. According to our summary of the study subjects\' demographic characteristics, most patients receiving preexisting antiplatelet agents were indeed older and had more comorbidities than did those without, and when estimates adjusted for confounders were pooled, the association between prestroke antiplatelet therapy and worse long‐term outcomes disappeared. It is important to point out, however, that even with the pooled adjusted estimate, we cannot guarantee that all possible confounders had been taken into account, as different adjustment variables were used in different studies.

We, therefore, carefully examined the characteristics of each study and conducted comprehensive subgroup analyses on more homogeneous subsets of data to further evaluate the impact of confounders on our results. Notably, those analyses also yielded some interesting practical and research implications. First, in one of the largest studies in this meta‐analysis (Xian et al[29](#jah31527-bib-0029){ref-type="ref"}), patient functional status was not evaluated on day 90, which is generally recognized as the most appropriate time point for final functional outcome assessment after acute ischemic stroke.[39](#jah31527-bib-0039){ref-type="ref"} It can be observed that there existed a significant discrepancy between the findings of this study and the results of the other largest study[18](#jah31527-bib-0018){ref-type="ref"} that measured functional outcomes on day 90 (OR 1.16, 95% CI 1.09--1.24 versus OR 1.02, 95% CI 0.97--1.08), which suggested that the impact of prestroke antiplatelet therapy on functional outcomes after thrombolysis might possibly be time dependent. Second, there were obvious differences in the odds of sICH and favorable outcome among patients receiving different prestroke antiplatelet medications. Patients who were receiving the aspirin--clopidogrel regimen had the highest risk of developing sICH (adjusted OR 1.88, 95% CI 1.18--3.00), whereas those receiving aspirin were associated with better functional outcomes (mRS 0--2 adjusted OR 1.11 95% CI 1.00--1.24; mRS 0--1 adjusted OR 1.14, 95% CI 1.06--1.23). Taking together into consideration the fact that the combination of aspirin and clopidogrel has no absolute efficacious superiority over aspirin regarding either primary prevention of atherothrombotic events or secondary prevention of stroke,[40](#jah31527-bib-0040){ref-type="ref"}, [41](#jah31527-bib-0041){ref-type="ref"} it seems that more cautions need to be taken before such a regimen was prescribed for stroke prevention. Given those existing differences in how different agents affect the efficacy and safety of systemic thrombolysis, we might also expect distinct risk--benefit profiles and interactive characteristics of the newer antiplatelet medications (eg, ticagrelor), as well as other types of thrombolytics (eg, desmoteplase) in stroke patients. While those medications have already been proven safe and started to seek practical indications in the prevention and management of acute ischemic stroke,[42](#jah31527-bib-0042){ref-type="ref"}, [43](#jah31527-bib-0043){ref-type="ref"} it would be interesting to see how patient care could be improved when they were put into clinical practice.

The strength of the present study lies in the great sample size pooled from a large number of studies. This enabled us to combine both unadjusted and adjusted estimates on all of the 3 major postthrombolytic outcomes and to perform comprehensive subgroup analyses to thoroughly examine the relationship between prestroke antiplatelet medications and the therapeutic outcomes of tPA, which, to the best of our knowledge, no prior study has been able to achieve. However, our study has the following limitations. First, the inherent limitations of observational studies cannot be overcome by meta‐analysis. Because only retrospective studies were available for the present analysis, the overall quality of evidence of our study is low. Second, variations on the doses of prestroke antiplatelet therapy and the issue of patient compliance were not addressed in most of the included studies, which could in turn serve as a potential cause of bias in this study. It, therefore, needs to be noted that imprecise estimations might be made when our findings were applied in clinical settings, and considerations on when patients last received antiplatelet therapy and the actual dosages of their medications need to be taken. Third, the main results for sICH might be a relatively conservative estimation for sICH risk if definitions other than the NINDS criteria were used to diagnose sICH, because the odds estimates for NINDS sICH were the lowest in the 3 studies that reported separate sets of data based on different sICH definitions---which can be observed from the subgroup analysis results---and they were selected to represent those studies in the main analysis. However, when those data were replaced with the other sets of estimates, the increase in either the combined unadjusted or adjusted ORs of sICH turned out to be minimal. Fourth, the funnel plots of crude estimates for sICH were significantly asymmetric, which indicated possible publication bias. Because we limited our search to published articles only, the risk of missing data was inevitable. However, we believed that our search strategy was adequate, for additional searches of references did not provide additional studies, and further, we were able to confirm the reliability of our results by using the trim‐and‐fill method. Nevertheless, because neither the exact mechanism of publication bias nor that of the trim‐and‐fill method has been fully understood, a precise estimation of the impact of publication bias on the accuracy of our results was after all unattainable. Fifth, our study was also susceptible to outcome reporting bias. While much emphasis was laid on the association between prestroke antiplatelet therapy and post‐tPA sICH in most included studies, only a part of them reported data on long‐term outcomes, and even fewer provided adjusted estimates. As a result, there might be limitations on the generalizability of the present findings on functional outcomes and mortality.

Conclusions {#jah31527-sec-0022}
===========

Patients with acute ischemic stroke who were receiving long‐term antiplatelet medications were associated with greater risks of developing sICH after systemic thrombolysis, despite a relatively small overall excess. Although those patients were frequently observed to also have higher odds of death or of developing unfavorable functional outcomes in many studies, the overall independent association between prestroke antiplatelet therapy and worsened long‐term outcomes proved insignificant after adjustment for confounders. Nonetheless, it needs to be noticed that the impact of prestroke antiplatelet therapy on post‐thrombolytic outcomes might be dependent on time and antiplatelet agents, and further research is warranted to elucidate the mechanisms underlying those phenomena. Collectively, while a history of prior antiplatelet therapy should not be considered as an overall contraindication to systemic thrombolysis, concerns need to be raised on the efficacy and safety of tPA when it is administered to patients taking different kinds of prestroke antiplatelet medications.
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